Advertisement
Screener

Quantum Cyber N.V. (QUCY) Cash Flows From Used In Financing Activities

0.8 / 5 stars · 3/18 Roast Me

Quantum Cyber N.V. Cash Flows From Used In Financing Activities

Quantum Cyber N.V. (QUCY) reported Cash Flows From Used In Financing Activities of $2.68 million for the 6-month period ending 2025-06-30, per its 6-K filed 2025-09-26.

Financial Statements › Cash Flow › Financing Activities

ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2025-09-26

  • Quantum Cyber N.V. cash flows from used in financing activities for the quarter ending 2023-12-31 was $3.47M.
  • Quantum Cyber N.V. cash flows from used in financing activities for the quarter ending 2023-09-30 was $4.57M.
  • Quantum Cyber N.V. cash flows from used in financing activities for the quarter ending 2023-06-30 was $5.42M.
  • Quantum Cyber N.V. cash flows from used in financing activities for the quarter ending 2023-03-31 was $773.48K, a 96.79% decline year-over-year.
Period endCash Flows From Used In Financing Activities 3 monthCash Flows From Used In Financing Activities 6 monthCash Flows From Used In Financing Activities 9 monthCash Flows From Used In Financing Activities 12 month
2025-06-30$2.68M
6-K · filed 2025-09-26
2024-12-31$16.60M
20-F · filed 2025-03-31
2024-06-30$2.55M
6-K · filed 2025-09-26
2023-12-31$3.47M
derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31
$8.03M
derived: sum of 2 quarters · filed 2025-03-31
$13.45M
derived: sum of 3 quarters · filed 2025-03-31
$14.23M
20-F · filed 2025-03-31
2023-09-30$4.57M
derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16
$9.99M
derived: sum of 2 quarters · filed 2024-10-18
$10.76M
6-K · filed 2023-11-16
$10.65M
derived: sum of 4 quarters · filed 2025-03-31
2023-06-30$5.42M
derived: 6-K 6 month − 6-K 3 month · filed 2024-10-18
$6.19M
6-K · filed 2024-10-18
$6.08M
derived: sum of 3 quarters · filed 2025-03-31
$6.04M
derived: sum of 4 quarters · filed 2025-03-31
2023-03-31$773.48K
6-K · filed 2023-05-16
$663.97K
derived: sum of 2 quarters · filed 2025-03-31
$625.25K
derived: sum of 3 quarters · filed 2025-03-31
$606.41K
derived: sum of 4 quarters · filed 2025-03-31
2022-12-31-$109.51K
derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31
-$148.23K
derived: sum of 2 quarters · filed 2025-03-31
-$167.07K
derived: sum of 3 quarters · filed 2025-03-31
$23.94M
20-F · filed 2025-03-31
2022-09-30-$38.72K
derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16
-$57.56K
derived: sum of 2 quarters · filed 2023-11-16
$24.05M
6-K · filed 2023-11-16
2022-06-30-$18.84K
derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15
$24.09M
6-K · filed 2023-08-15
2022-03-31$24.11M
6-K · filed 2023-05-16
2021-12-31$10.61M
20-F · filed 2024-04-09
2021-06-30$217.03K
6-K · filed 2022-09-07
2020-12-31$396.68K
20-F · filed 2023-04-07
2019-12-31$424.00K
20-F · filed 2022-05-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
Immuneering Corp (IMRX)United States$0.113B-12.51
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
GENELUX Corp (GNLX)United States$0.110B-3.83
Equillium, Inc. (EQ)United States$0.109B-11.27
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80